BMY - Exelixis initiates Phase 1b XL092 combo trial in solid tumors

Exelixis (NASDAQ:EXEL) announces initiation of the dose-escalation stage of STELLAR-002, a phase 1b trial evaluating XL092 in combination with immuno-oncology therapies in advanced solid tumors. The objective of the study is to evaluate the safety, tolerability and efficacy of XL092, in combination with: Bristol-Myers Squibb's (NYSE:BMY) nivolumab (Opdivio); nivolumab and ipilimumab (Yervoy); and nivolumab and bempegaldesleukin. Nektar Therapeutics (NASDAQ:NKTR) will supply bempegaldesleukin to BMY through their existing collaboration. The dose-escalation stage will determine the recommended dose in patients with advanced solid tumors for each of the XL092 combination therapy regimens. Once the recommended dose is established, the trial will begin to enroll tumor-specific expansion cohorts for patients with advanced renal cell carcinoma, urothelial carcinoma and metastatic castration-resistant prostate cancer.

For further details see:

Exelixis initiates Phase 1b XL092 combo trial in solid tumors